

**Total revenues**

The following table provides an analysis of the Company's total revenues by source:

(In millions, except %)	For the years ended December 31,		
	2016	2015	Change %
Product sales	\$ 10,885.8	\$ 6,099.9	78%
Royalties and other revenues	510.8	316.8	61%
<b>Total</b>	<b>\$ 11,396.6</b>	<b>\$ 6,416.7</b>	<b>78%</b>

**Product sales**

(In millions, except %)	For the years ended December 31,		Product sales growth %
	2016	2015	
<b>Product sales:</b>			
HEMOPHILIA	\$ 1,789.0	\$ —	N/A
INHIBITOR THERAPIES	451.8	—	N/A
<b>Hematology total</b>	<b>2,240.8</b>	<b>—</b>	<b>N/A</b>
CINRYZE	680.2	617.7	10.1 %
ELAPRASE	589.0	552.6	6.6 %
FIRAZYR	578.5	445.0	30.0 %
REPLAGAL	452.4	441.2	2.5 %
VPRIV	345.7	342.4	1.0 %
KALBITOR	52.2	—	N/A
<b>Genetic Diseases total</b>	<b>2,698.0</b>	<b>2,398.9</b>	<b>12.5 %</b>
VYVANSE	2,013.9	1,722.2	16.9 %
ADDERALL XR	363.8	362.8	0.3 %
Other Neuroscience	112.8	115.4	(2.3)%
<b>Neuroscience total</b>	<b>2,490.5</b>	<b>2,200.4</b>	<b>13.2 %</b>
IMMUNOGLOBULIN THERAPIES	1,143.9	—	N/A
BIO THERAPEUTICS	372.2	—	N/A
<b>Immunology total</b>	<b>1,516.1</b>	<b>—</b>	<b>N/A</b>
LIALDA/MEZAVANT	792.1	684.4	15.7 %
PENTASA	309.4	305.8	1.2 %
GATTEX/REVESTIVE	219.4	141.7	54.8 %
NATPARA	85.3	24.4	249.6 %
Other Internal Medicine	349.3	344.3	1.5 %
<b>Internal Medicine total</b>	<b>1,755.5</b>	<b>1,500.6</b>	<b>17.0 %</b>
<b>Oncology total</b>	<b>130.5</b>	<b>—</b>	<b>N/A</b>
<b>Ophthalmology Total</b>	<b>54.4</b>	<b>—</b>	<b>N/A</b>
<b>Total Product sales</b>	<b>\$ 10,885.8</b>	<b>\$ 6,099.9</b>	<b>78.5 %</b>

**Hematology**

Hematology, acquired with Baxalta in June 2016, includes sales of recombinant and plasma-derived hemophilia products (primarily factor VIII and factor IX) and inhibitor therapies. Product sales of the franchise for the year ended December 31, 2016 were \$2,241 million.